Spirotetramat - CAS:203313-25-1

您当前的位置：

Spirotetramat (Synonyms:螺虫乙酯; BY-108330)

目录号 : KCM12410 CAS No. : 203313-25-1 纯度 : ≥90%

Data Sheet SDS 产品使用指南

Spirotetramat is an insecticide. It is active against C. pyri nymphs in vitro (LC = 6.51-12.53 mg AI/L) and induces mortality of C. pyri nymphs in European pear (P. communis) fields by 99.2% 15 days after application at a concentration of 27 g/hectare. Spirotetramat also reduces O. insidiosus embryonic viability and nymph survival. It exhibits aquatic toxicity, increasing expression of glutathione peroxidase (Gpx) and superoxide dismutase (SOD), decreasing production of malondialdehyde (MDA), and inducing lethality in Chinese toad (B. gargarizans) tadpoles (LC = 6.98 mg/L).

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock
10 mM * 1 mL in DMSO		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Spirotetramat In-stock
Methiocarb In-stock
EUK 124 In-stock
EUK 118 In-stock
Salicylcurcumin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Spirotetramat is an orally active Insecticide and lipid biosynthesis inhibitor. Spirotetramat regulates the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), with short-term exposure increasing their activities and long-term exposure altering their activities. Spirotetramat induces the activity and mRNA expression of carboxylesterase (CarE). Spirotetramat induces oxidative stress and lipid peroxidation in tadpoles. Spirotetramat is toxic to amphibian tadpoles and exhibits sublethal/non-lethal toxicity to amphibians. Spirotetramat causes death in immature psyllids, aphids, scale insects, mealybugs, whiteflies and thrips, and shows a high lethal rate against Cacopsylla pyri nymphs. Spirotetramat reduces the fecundity of Aphis gossypii. Spirotetramat induces tolerance in the offspring of exposed Aphis gossypii, and acts on Myzus persicae, Bemisia tabaci and Tetranychus urticae.

体外研究

Spirotetramat (0.48-120.0 mg AI liter-1; 10 days) showed potent activity against Cacopsylla pyri nymphs of FE1, FE2, FE3, and FE4 populations, with LC90 values ranging from 67.3 to 125.22 mg AI liter-1 and no obvious signs of resistance development (all RF90 values<5) .
The toxicity of Spirotetramat (3.75-1920 mg/L; 1-5 days) to 4-day-old cotton aphids increased with prolonged exposure time, and its LC50 reached 12.3 mg/L after 5 days of exposure.
Spirotetramat (8 days) can decrease the reproductive capacity of 4-day-old cotton aphids in a concentration dependent manner. On the 8th day of exposure, LC75 concentration can reduce the offspring yield to 6.7% of the control group level .
Spirotetramat (53.9 mg/L; 5 days) significantly increased the carboxylesterase activity of cotton aphids within 5 days, reaching 3361 Δ OD min-1 mg-1 on the 5th day .
Spirotetramat (53.9 mg/L; 1-5 days) upregulated the mRNA expression of CarE-YS1 in cotton aphids in a time-dependent manner, with a 5.2-fold increase compared to the control group on the 5th day of exposure.
Spirotetramat (53.9 mg/L; 5 days) increased the tolerance of Aphis gossypii offspring exposed to the drug by 2.5 times, with an LC50 of 28.4 mg/L, compared to 11.6 mg/L in the control group offspring.

体内研究

Spirotetramat (4.00-8.00 mg/L; aquatic exposure; continued; 96 hours) showed moderate acute toxicity to tadpoles of the Chinese toad, with a 96 hour LC50 of 6.45 mg/L, and the toxicity increased with increasing concentration and prolonged exposure time.
Spirotetramat (0.03-3.23 mg/L; continuous exposure to aquatic environments; 4-30 days) can induce oxidative stress and alter lipid peroxidation levels in Chinese toad tadpoles, with GSH Px activity being the most sensitive indicator, manifested as sustained inhibition after initial activation.

Animal Model:	Bufo bufo gargarizans (Gosner stages 33-35, healthy, same-size individuals)
Dosage:	4.00 mg/L, 4.60 mg/L, 5.30 mg/L, 6.10 mg/L, 7.00 mg/L, 8.00 mg/L
Administration:	aquatic exposure; continuous; 96 h
Result:	Showed no mortality in the 4.00 mg/L and 4.60 mg/L groups over 96 h. Recorded first mortality at 72 h in the 5.30 mg/L (2 deaths) and 6.10 mg/L (3 deaths) groups, increasing to 5 and 6 deaths, respectively, by 96 h. Observed mortality as early as 24 h in the 7.00 mg/L (1 death) and 8.00 mg/L (1 death) groups, increasing to 22 and 29 deaths, respectively, by 96 h. Determined the 72 h median lethal concentration (LC₅₀) as 6.98 mg/L, and the 96 h LC₅₀ as 6.45 mg/L. Induced poisoning symptoms including slow swimming/breathing, reduced swimming ability, weak activity, and fading body color in tadpoles exposed to higher concentrations.

Animal Model:	Bufo bufo gargarizans (Gosner stages 33-35, healthy, same-size individuals)
Dosage:	0.03 mg/L, 0.06 mg/L, 0.13 mg/L, 0.65 mg/L, 3.23 mg/L
Administration:	aquatic exposure; continuous; 4, 15, or 30 days
Result:	Increased SOD activity significantly (P < 0.05) in all groups except the 3.23 mg/L group after 4 days of exposure compared to the control. Decreased SOD activity significantly (P < 0.05) in the 0.65 mg/L group after 15 days compared to its 4-day value, with no significant differences between any treatment group and the control. Showed no significant differences in SOD activity between treatment groups (except 0.65 mg/L) and the control after 30 days. Increased GSH-Px activity significantly (P < 0.05) in the 0.06 mg/L, 0.13 mg/L, 0.65 mg/L, and 3.23 mg/L groups after 4 days of exposure compared to the control. Inhibited and decreased GSH-Px activity significantly (P < 0.05) in all groups except the 0.13 mg/L group after 15 and 30 days compared to the control and 4-day values. Showed no significant differences in MDA content between treatment groups and the control after 4 or 15 days. Decreased MDA content significantly (P < 0.05) in the 0.13 mg/L, 0.65 mg/L, and 3.23 mg/L groups after 30 days compared to the control.

分子式

C₂₁H₂₇NO₅

分子量

373.44

CAS号

203313-25-1

中文名称

螺虫乙酯;

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 50 mg/mL (133.89 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6778 mL	13.3890 mL	26.7781 mL
5 mM	0.5356 mL	2.6778 mL	5.3556 mL
10 mM	0.2678 mL	1.3389 mL	2.6778 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.69 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (6.69 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.69 mM) 的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO → 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.69 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。